SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-24-036864
Filing Date
2024-08-13
Accepted
2024-08-13 08:59:27
Documents
70
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q mrsn-20240630.htm   iXBRL 10-Q 1342449
2 EX-31.1 exhibit31110-qfy2024q2.htm EX-31.1 11100
3 EX-31.2 exhibit31210-qfy2024q2.htm EX-31.2 11118
4 EX-32.1 exhibit32110-qfy2024q2.htm EX-32.1 5741
  Complete submission text file 0001628280-24-036864.txt   5893941

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrsn-20240630.xsd EX-101.SCH 36906
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrsn-20240630_cal.xml EX-101.CAL 49793
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrsn-20240630_def.xml EX-101.DEF 151932
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrsn-20240630_lab.xml EX-101.LAB 519412
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrsn-20240630_pre.xml EX-101.PRE 367917
73 EXTRACTED XBRL INSTANCE DOCUMENT mrsn-20240630_htm.xml XML 671201
Mailing Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 617-498-0020
Mersana Therapeutics, Inc. (Filer) CIK: 0001442836 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38129 | Film No.: 241199013
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)